Previous Page  106 / 490 Next Page
Information
Show Menu
Previous Page 106 / 490 Next Page
Page Background

104

SCIENTIFIC PROGRAMME

| PROGRAMME AND EXHIBITION GUIDE

SUNDAY 1 MAY 2016

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

14:30 > Standardisation and treatment planning

Speaker: B. Heijmen (The Netherlands), A. Henry, S. Breedveld

SP-0292

14:45 > Potentials and challenges of automated contouring in treatment

planning

Speaker: S. Pallotta (Italy)

SP-0293

15:00 > Implementation of new standards in your department: an RTT

perspective

Speaker: A. Baker (UK), Y. Tsang

SP-0294

15:15 > Improvement of delineation quality of organs at risk in head and neck

using the consensus guidelines

R. Steenbakkers (The Netherlands), C. Brouwer, J. Bourhis, W. Budach,

C. Grau, V. Grégoire, M. Van Herk, A. Lee, P. Maingon, C. Nutting,

B. O’Sullivan, S. Porceddu, D. Rosenthal, N. Sijtsema, J. Langendijk

OC-0295

Symposium

DNA REPAIR INHIBITION AND RADIOTHERAPY: MOVING TOWARDS

CLINIC

14:15 - 15:30 | LONDRA

For many years the radiosensitising effects of DNA repair inhibitors have been presented at ESTRO.

But only recently have these agents progressed to clinical testing in combination with radiotherapy and

systemic anti-cancer agents.

In this symposium three internationally leading researchers will present groundbreaking work evaluating

the most advanced class of DNA repair antagonists: PARP inhibitors.

Jan Schellens will report on studies combining PARP inhibitors with chemotherapy while Marcel Verheij

will describe the challenges associated with combining PARP inhibitors and radiation. Finally David

Raben will present a novel strategy combining PARP inhibition with radiation and the EGFR targeting

agent cetuximab.

Chair: A. Chalmers (UK)

Co-chair: M. Buglione (Italy)

14:15 > Challenges in combining radiation and chemo-radiation with PARP

inhibitors

Speaker: J. Schellens (The Netherlands)

SP-0296

14:40 > Results of phase I trials combining PARP inhibition and radiotherapy in

multiple sites

Speaker: M. Verheij (The Netherlands)

SP-0297

15:05 > Phase I results of PARP Inhibition + Radiation + Cetuximab in heavy

smoker LAHNSCC

Speaker: D. Raben (USA)

SP-0298